Elimination of Minimal Residual Disease After Transplant
NCT05690984
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is going to look at patients with a type of cancer called multiple myeloma. These patients will have already had a type of treatment called a stem cell transplant, but they still have some cancer cells in their bone marrow. The study will include these patients, no matter how well the other doctors think their treatment is working.
This study is going to look at patients with a type of cancer called multiple myeloma. These patients will have already had a type of treatment called a stem cell transplant, but they still have some cancer cells in their bone marrow. The study will include these patients, no matter how well the other doctors think their treatment is working.
Third Opinion AI Generated Synopsis
Trial Summary
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
